OncoTargets and Therapy (Sep 2018)

A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab

  • Sugano T,
  • Seike M,
  • Noro R,
  • Kaburaki S,
  • Tozuka T,
  • Takahashi A,
  • Takano N,
  • Tanaka T,
  • Kashiwada T,
  • Takeuchi S,
  • Minegishi Y,
  • Saito Y,
  • Kubota K,
  • Terasaki Y,
  • Gemma A

Journal volume & issue
Vol. Volume 11
pp. 5879 – 5883

Abstract

Read online

Teppei Sugano,1 Masahiro Seike,1 Rintaro Noro,1 Syota Kaburaki,1 Takehiro Tozuka,1 Akihiko Takahashi,1 Natsuki Takano,1 Toru Tanaka,1 Takeru Kashiwada,1 Susumu Takeuchi,1 Yuji Minegishi,1 Yoshinobu Saito,1 Kaoru Kubota,1 Yasuhiro Terasaki,2 Akihiko Gemma1 1Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan; 2Department of Analytic Human Pathology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan Abstract: We herein describe the case of a 67-year-old woman with advanced lung adenocarcinoma who developed interstitial lung disease (ILD) with alveolar hemorrhage induced by pembrolizumab. She received four courses of pembrolizumab therapy and achieved a partial response. She had no respiratory symptoms; however, chest radiography and computed tomography (CT) revealed ground-glass opacities (GGOs) and crazy-paving pattern. Based on findings of bloody bronchoalveolar lavage fluid and transbronchial lung biopsy samples, pembrolizumab-induced ILD with alveolar hemorrhage was diagnosed. Corticosteroid therapy rapidly improved alveolar hemorrhage and regressed GGOs on CT scan. This is the first report on ILD with alveolar hemorrhage induced by pembrolizumab. Keywords: pembrolizumab, PD-1, pneumonitis, alveolar hemorrhage

Keywords